Compare RYOJ & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYOJ | RNTX |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | Japan | United States |
| Employees | N/A | 11 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8M | 30.0M |
| IPO Year | N/A | N/A |
| Metric | RYOJ | RNTX |
|---|---|---|
| Price | $2.27 | $1.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 28.4K | ★ 80.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.81 | $1.02 |
| 52 Week High | $11.43 | $2.22 |
| Indicator | RYOJ | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.29 | 49.01 |
| Support Level | $1.84 | $1.06 |
| Resistance Level | $2.39 | $1.30 |
| Average True Range (ATR) | 0.24 | 0.11 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 10.00 | 46.15 |
rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.